by ZPHC
Retatrutide 15mg single vial by ZPHC. Starter dose for triple agonist research.
In stock
Pay with Bitcoin or USDT (TRC-20) on this site, or contact a representative for a card or bank payment link. Free EU shipping over €250.
Batch certificate of analysis available on request via Telegram or the contact form.
ZPHC Retatrutide 15mg is a single-vial lyophilized formulation of the triple GIP/GLP-1/glucagon agonist. The 15mg single-vial format is ideal for entry-level research dosing. Phase 3 data show Retatrutide achieving ~24% weight reduction at higher doses — significantly outperforming all prior GLP-1 agents.
For laboratory research use only.
Weight Loss & GLP-1
GLP-1 receptor agonist research is evolving rapidly beyond injectable semaglutide: oral formulations, triple agonists (GLP-1/GIP/glucagon), CNS-targeted analogs, and organ-protective applications. Research guide to the next-generation GLP-1 pipeline and the mechanistic frontiers being explored in 2025–2026.
6 min read
Peptides & Recovery
GLP-1 receptor agonists improve insulin resistance through multiple mechanisms beyond GLP-1R signaling — including hepatic gluconeogenesis suppression, adipose tissue remodeling, and GIP receptor co-stimulation. Advanced research guide to GLP-1 insulin sensitization pathways and experimental models.
5 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Must be handled by qualified professionals in a controlled laboratory setting. JuicedPharma makes no therapeutic or medical claims about this compound.
Hilma Biocare
Triple GIP/GLP-1/Glucagon agonist. Next-generation metabolic research compound.
98.5%· Janoshik
ZPHC
Retatrutide 10mg (5×2mg) lyophilized by ZPHC. Triple GIP/GLP-1/Glucagon agonist.
99%+· ZPHC
ZPHC
Retatrutide 20mg kit (5×4mg) by ZPHC. GIP/GLP-1/Glucagon triple agonist.
99%+· ZPHC
ZPHC
Retatrutide 30mg premixed AQ auto-injector pen by ZPHC. Ready-to-use.
99%+· ZPHC
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer